615 related articles for article (PubMed ID: 19393232)
1. Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or/and duplication of the CYP2D6 gene.
Arneth B; Shams M; Hiemke C; Härtter S
Clin Biochem; 2009 Aug; 42(12):1282-90. PubMed ID: 19393232
[TBL] [Abstract][Full Text] [Related]
2. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
Dorado P; Cáceres MC; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
Biotechniques; 2005 Oct; 39(4):571-4. PubMed ID: 16235570
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR.
Schaeffeler E; Schwab M; Eichelbaum M; Zanger UM
Hum Mutat; 2003 Dec; 22(6):476-85. PubMed ID: 14635107
[TBL] [Abstract][Full Text] [Related]
4. Characterization of cytochrome P450 2D6 alleles using the Invader system.
Nevilie M; Selzer R; Aizenstein B; Maguire M; Hogan K; Walton R; Welsh K; Neri B; de Arruda M
Biotechniques; 2002 Jun; Suppl():34-8, 40-3. PubMed ID: 12083395
[TBL] [Abstract][Full Text] [Related]
5. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.
Shams ME; Arneth B; Hiemke C; Dragicevic A; Müller MJ; Kaiser R; Lackner K; Härtter S
J Clin Pharm Ther; 2006 Oct; 31(5):493-502. PubMed ID: 16958828
[TBL] [Abstract][Full Text] [Related]
6. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.
Bathum L; Johansson I; Ingelman-Sundberg M; Hørder M; Brøsen K
Pharmacogenetics; 1998 Apr; 8(2):119-23. PubMed ID: 10022749
[TBL] [Abstract][Full Text] [Related]
7. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
Dorado P; Cáceres M; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
Biotechniques; 2005 Oct; 39(10 Suppl):S571-4. PubMed ID: 18957039
[TBL] [Abstract][Full Text] [Related]
8. TaqMan real-time PCR quantification strategy of CYP2D6 gene copy number for the LightCycler 2.0.
Nguyen DL; Staeker J; Laika B; Steimer W
Clin Chim Acta; 2009 May; 403(1-2):207-11. PubMed ID: 19296901
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly.
Whyte EM; Romkes M; Mulsant BH; Kirshne MA; Begley AE; Reynolds CF; Pollock BG
Int J Geriatr Psychiatry; 2006 Jun; 21(6):542-9. PubMed ID: 16642541
[TBL] [Abstract][Full Text] [Related]
10. Correlation between cytochrome P-450 CYP2D6 (CYP2D6) genotype and phenotype.
Chen SQ; Wedlund PJ
Zhongguo Yao Li Xue Bao; 1999 Jul; 20(7):585-8. PubMed ID: 10678117
[TBL] [Abstract][Full Text] [Related]
11. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.
Rau T; Wohlleben G; Wuttke H; Thuerauf N; Lunkenheimer J; Lanczik M; Eschenhagen T
Clin Pharmacol Ther; 2004 May; 75(5):386-93. PubMed ID: 15116051
[TBL] [Abstract][Full Text] [Related]
12. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry.
Chen S; Chou WH; Blouin RA; Mao Z; Humphries LL; Meek QC; Neill JR; Martin WL; Hays LR; Wedlund PJ
Clin Pharmacol Ther; 1996 Nov; 60(5):522-34. PubMed ID: 8941025
[TBL] [Abstract][Full Text] [Related]
13. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction.
Rebsamen MC; Desmeules J; Daali Y; Chiappe A; Diemand A; Rey C; Chabert J; Dayer P; Hochstrasser D; Rossier MF
Pharmacogenomics J; 2009 Feb; 9(1):34-41. PubMed ID: 18591960
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous genotyping of CYP2D6*3, *4, *5 and *6 polymorphisms in a Spanish population through multiplex long polymerase chain reaction and minisequencing multiplex single base extension analysis.
Crescenti A; Mas S; Gassó P; Baiget M; Bernardo M; Lafuente A
Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):992-7. PubMed ID: 17714084
[TBL] [Abstract][Full Text] [Related]
15. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy].
Szewczuk-Bogusławska M; Grzesiak M; Beszłej JA; Kiejna A
Psychiatr Pol; 2004; 38(6):1093-104. PubMed ID: 15779673
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
[TBL] [Abstract][Full Text] [Related]
18. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G
Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553
[TBL] [Abstract][Full Text] [Related]
19. Effect of tolterodine on sleep structure modulated by CYP2D6 genotype.
Diefenbach K; Jaeger K; Wollny A; Penzel T; Fietze I; Roots I
Sleep Med; 2008 Jul; 9(5):579-82. PubMed ID: 17921051
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. IV. Application of long polymerase chain reaction for identification of CYP2D6 gene duplication.
Pułczyńska A; Łukaszkiewicz J; Wojnar M; Tomaszewski P; Kubiak-Tomaszewska G; Pachecka J
Acta Pol Pharm; 2011; 68(1):9-13. PubMed ID: 21485696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
